title: Industry chases pan-genotypic and shorter HCV treatments.
authors.forename: Anna
authors.initials: A
authors.lastname: Azvolinsky
mesh_terms: D004345:Drug Industry; D015894:Genome, Human; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D012324:RNA-Dependent RNA Polymerase
chemical_list: D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase